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Azacitidine (5-azacytidine, Vidaza [Celgene Corporation, USA]) is a cytidine analogue that was approved in 2004 for the treatment 
of all myelodysplastic syndrome (MDS) subtypes (1-5). Azacitidine 
has two main mechanisms of antineoplastic action: cytotoxic activity 
through the inhibition of nucleic acid synthesis via incorporation into 
DNA and RNA as an analogue of cytidine, and DNA hypomethyla-
tion, and restoration of normal growth control and differentiation of 
hematopoetic cells (1,2).  
The safety of azacitidine has been studied in phase III clinical trials 
(4). The adverse effects observed were mainly cytopenias; no oppor-
tunistic infections were reported (1,2). The drug is not believed to 
cause significant immunosuppression.  
We report a case of cytomegalovirus (CMV) colitis in a patient 
treated with azacitidine for MDS. To our knowledge, the present 
report is the first to describe this opportunistic infection in a patient 
treated with azacitidine.
Case presentation
A 66-year-old Caucasian woman was diagnosed with the chronic 
myelomonocytic leukemia MDS subtype in October 2007, after pre-
senting with pancytopenia, splenomegaly, fatigue and weight loss over 
a four-month period. Her medical history included spinal stenosis, 
degenerative disc disease and carpal tunnel syndrome. In August 2009, 
due to worsening cytopenias and transfusion dependence, the decision 
was made to begin treatment with azacitidine, starting in September 
2009. The dosing schedule was 75 mg/m2 for seven consecutive days, 
every 28 days. Following monthly doses, her total white blood cell 
count dropped only slightly, from 2.0×109/L to 2.5×109/L, to 1.5×109/L 
to 1.7×109/L.
On January 21, 2010, after having undergone five cycles of therapy, 
she presented to the emergency room with fever, abdominal cramping and 
rectal bleeding. Her urine output was decreased. The patient’s  physical 
examination demonstrated a regular heart rate of 110 beats/min, a blood 
pressure of 100/50 mmHg and a temperature of 38.4°C. She appeared 
unwell. Her jugular venous pulsation was weak, and her abdomen was 
tender in both lower quadrants. There was no hepatosplenomegaly. 
Her bowel sounds were present, and there was no rebound tenderness. 
She also experienced mild fecal incontinence. Erythema was present 
in the perianal area; however, a digital rectal examination was not 
performed.
Her white blood cell count was 1.0×109/L, with an absolute 
neutrophil count of 0.4×109/L and an absolute lymphocyte count of 
0.5×109/L. Her hemoglobin level was 84 g/L, and platelet count was 
71×109/L. The patient’s electrolyte, urea, creatinine, lactate dehydro-
genase, aspartate aminotransferase, alanine transaminase, alkaline 
phosphatase, amylase, calcium, albumin and magnesium levels were all 
within normal limits. Her total bilirubin level was elevated to 
29 µmol/L, and her inorganic phosphate level was decreased to 
0.70 mmol/L. The patient’s chest radiograph showed mild chronic 
changes. A computed tomography scan of her abdomen showed “ill-
defined thickening of the rectal wall, with minimal stranding within 
the mesorectal fat and fascia which is associated with increased soft 
tissue density in the presacral space”.
The patient was admitted to the hematology service with a diagno-
sis of febrile neutropenia. Blood cultures were drawn, and she was 
treated with intravenous antibiotics including ceftazidime, metronidaz-
ole and imipenem. The patient showed signs of very mild clinical 
improvement. Her blood cultures were negative after seven days.  
Due to continued rectal bleeding, and abdominal and rectal pain, 
the patient underwent sigmoidoscopy on January 27, which showed 
the distal 7 cm to 8 cm of her rectal mucosa to be “markedly inflamed 
and ulcerated” (Figures 1A and 1B). The patient underwent a rectal 
biopsy, which was reported as “active inflammation with viral effects, 
compatible with CMV-like colitis”. The CMV immunohistochemical 
stain was positive (Figure 1C), CMV immunoglobulin G antibody was 
reactive, CMV immunoglobulin M antibody was nonreactive, CMV 
shell-vial culture was negative and the CMV viral load was not avail-
able at the time of diagnosis. Based on immunohistochemical staining 
performed on the biopsy tissue, a diagnosis of CMV colitis was made. 
Intravenous antibiotics were discontinued, and therapy with intra-
venous ganciclovir was initiated on January 28, 2010, at a dose of 
250 mg every 12 h.  
At this point, the infectious diseases department was consulted. 
Azacitidine was held. Repeat sigmoidoscopy was undertaken on 
February 18, 2008, which showed dramatic improvement in rectal 
inflammation, with the only abnormality being a small area of 
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The present report describes the first recognized case of cytomegalovirus 
(CMV) colitis following azacitidine therapy. A 66-year-old woman with 
myelodysplastic syndrome developed CMV colitis, which responded to 
treatment with ganciclovir. Currently, patients receiving azacitidine do not 
undergo CMV testing, or receive prophylaxis or CMV-free blood products; 
however, this policy needs to be revised.
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La colite à cytomégalovirus après une thérapie 
à l’azacitidine 
Le présent rapport décrit le premier cas démontré de colite à cytomégalovirus 
(CMV) après une thérapie à l’azacitidine. Une femme de 66 ans atteinte 
du syndrome myélodysplasique a souffert d’une colite à CMV qui a réagi à 
un traitement au ganciclovir. Les patients qui prennent de l’azacitidine ne 
subissent pas de test de CMV et ne reçoivent pas de prophylaxie ou de 
produits sanguins sans CMV. Cependant, cette politique doit être révisée.
Khan et al
Can J Infect Dis Med Microbiol Vol 22 No 3 Autumn 2011e22
erythema in the sigmoid colon (at 25 cm from the rectum) (Figure 1D). 
Repeat biopsies of the sigmoid colon and rectum showed mild to mod-
erate chronic inflammation with no definite morphological evidence 
of viral inclusions. Repeat CMV immunohistochemical stains were 
negative. Ganciclovir was discontinued at this point, after a total dur-
ation of three weeks, and the patient was discharged home.
The suggestion of the infectious diseases department was to mon-
itor the serial CMV viral load for viral re-activation if the patient was 
to be treated further with azacitidine. No CMV suppression was rec-
ommended at the time of hospital discharge. The patient has received 
several more cycles of azacytidine since her discharge from the hospi-
tal. Most recent bloodwork showed a white blood cell count of 
3.6×109/L, with an absolute neutrophil count of 1.5×109/L, hemoglo-
bin level of 115 g/L and a platelet count of 172×109/L. She continues 
to do well on azacitidine treatment, with no further gastrointestinal 
symptoms, and is no longer dependent on red cell transfusions. 
Monthly viral loads have been undetectable since the time of dis-
charge (seven months ago).
DisCussion
We describe a case of CMV colitis in a 66-year-old woman treated 
with azacitidine for MDS. To our knowledge, this is the first report of 
this opportunistic infection in a patient treated with this medication.  
Adverse events have been reported with the use of azacitidine 
including nonspecific gastrointestinal symptoms (nausea, vomiting, 
diarrhea, constipation and anorexia), hematological events (neutro-
penia, anemia and thrombocytopenia), injection site events, arthral-
gia, cough, dyspnea, headache, dizziness, weakness and insomnia. 
Reported hospitalizations were from thrombocytopenia, febrile neutro-
penia, fever and pneumonia.  However, none of these symptoms have 
been attributed to CMV infection (1,2).
In our patient, there was a dramatic response, both clinically and 
endoscopically, to treatment with intravenous ganciclovir. No formal 
guidelines for duration of therapy exist in this circumstance. Our deci-
sion to treat for three weeks was based on the patient’s clinical and 
endoscopic response to ganciclovir treatment.
It is not clear, in the present case, whether there was latent CMV 
infection, which was reactivated by azacitidine, or whether primary 
infection with CMV occurred after initiation of azacitidine treatment 
because CMV serology was not performed before azacitidine treatment.
Azacitidine is known to activate CMV transcription promoters in 
vitro (6) and in vivo (7). In fact, the drug is used to facilitate gene 
transfer of viral vectors for cancer treatment (8), which is believed to 
occur through the drug’s effect on DNA promoter demethylation and 
activation of the nuclear factor-kappa B pathway. Whether azacitidine 
used for treatment of MDS has any effect on reactivation of latent 
CMV in MDS patients is unknown.  
Although severe CMV infections, including colitis (9), can affect 
immunocompetent hosts (10), it is generally an infection that occurs 
during profound immunosuppression including late-stage HIV infection 
(11) and following bone marrow transplant (12). Generally, conven-
tional chemotherapies that do not cause lymphopenia or alterations in 
lymphocyte function are not considered to be high risk for the develop-
ment of CMV disease (13,14). However, isolated cases of CMV colitis 
have been reported after conventional chemotherapy for testicular can-
cer (15), non-Hodgkin’s lymphoma (16), hypopharyngeal cancer (17), 
pancreatic carcinoma (18) and small cell lung cancer (19). CMV dis-
ease of other organ systems after conventional chemotherapy has also 
been reported (20). Furthermore, a recent study (21) suggested that 
there may be a high incidence of CMV reactivation in patients under-
going conventional chemotherapy. 
The optimal approach to prevention in compromised hosts is not 
clear because both prophylactic and pre-emptive treatment approaches 
have advantages (22). There is no existent policy in Canada for CMV 
screening before initiation of azacitidine therapy, or for CMV chemo-
prophylaxis in patients known to have chronic CMV infection while 
being treated with azacitidine. Patients on azacitidine are not generally 
given CMV-free transfusions.  Further study of the relationships among 
azacitidine, CMV promoter activation, and acute or re-activated CMV 
infection are needed to answer these questions. We suggest that CMV 
testing, monitoring and prophylaxis may be required in patients 
receiving azacitidine.
ConfLiCts of interest: This report received no financial sup-
port, and the authors have no conflicts of interest to declare.
figure 1) Sigmoidoscopy and cytomegalovirus immunostaining. Photos 
taken during sigmoidoscopy before (a, B) and after (C) treatment with 
intravenous ganciclovir. Immunostaining performed on the biopsy taken 
during colonoscopy shown in panel A stained positive for cytomegalovirus 
(D), original magnification ×100
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